3 stories tagged with #zumilokibart, in publish-time order across the WeSearch catalog. Tag pages update as new stories ingest.
⌘ RSS feed for this tag → or search "Zumilokibart"
RELATED TAGS
SEEKING ALPHA
Apogee Therapeutics: Charging Toward Pivotal Eczema Trial With Extended Dosing
Apogee Therapeutics, Inc. rated Buy: zumilokibart Phase 2b AD results, 2–4 doses/yr, Blackstone $1.3B funding; fair value $82.97—read now. Click for an APGE update.…
INVESTING.COM — NEWS
Apogee’s zumilokibart meets Phase 2 trial endpoints in dermatitis
SEEKING ALPHA
Apogee Therapeutics: Targeting Atopic Dermatitis
Apogee Therapeutics, Inc. is rated a Hold, driven by promising data for the lead asset zumilokibart in atopic dermatitis. Read more on APGE stock here.…